Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback